最新精编医学专题—肺癌同步放化疗进展.ppt

同步(tóngbù)放化疗在NSCLC的进展主要(zhǔyào)内容放疗在早期NSCLC的进展同步(tóngbù)放化疗与靶向药物治疗NSCLC的进展同步放化疗联合培美曲塞治疗NSCLC的研究进展同步放化疗在晚期NSCLC的进展Stereotacticablativeradiotherapy(SABR)inpotentiallyoperableStageInon-smallcelllungcancerpatientsI期NSCLC经SABR治疗(zhìliáo)后的局部控制情况不选择(xuǎnzé)手术的原因SABR对潜在科手术(shǒushù)病人的基线特征SABR的治疗剂量(jìliàng)选择SABR的主要(zhǔyào)毒性SABR治疗117例潜在可手术(shǒushù)患者的结果结论(jiélùn)LCCC0511:PhaseI/IITrialofInductionCarboplatin/PaclitaxelplusBevacizumabfollowedbyConcurrentThoracicConformalRadiotherapywithCarboplatin/PaclitaxelBevacizumabandErlotinibinStageIIIA/BNSCLC实验设计入组病人(bìngrén)基线特征发生率多于等于1个病人且大于等于3级的毒性(dúxìnɡ)统计反应(fǎnyìng)率–RECIST(n=45)LCCC生存(shēngcún)结果LCCC高剂量(jìliàng)同步放化疗的相关临床实验LCCC0511-结论(jiélùn)MultimodAlitytreatmentwithRadio-chemoTherapyandErlotinibinadvancedNSCLC(MARTEtrial)进展期NSCLC放化疗联合厄罗替尼的多模式治疗(zhìliáo)（MARTE实验）材料(cáiliào)和方法病人基线特征和治疗(zhìliáo)相关毒性病人基线特征(tèzhēng)和毒性统计数据有效性结论(jiélùn)Determinationofstandarddosecetuximabtogetherwithconcurrentindividualisedisotoxicacceleratedradiotherapyandcisplatin-vinorelbineforpatientswithstageIIInon-smallcelllungcancer:AphaseIstudy(NCT00522886)治疗(zhìliáo)流程表毒性(dúxìnɡ)治疗3个月后经FDG-PET测定代谢反应(N=22)•CR:8•PR:11•PD:3结论(jiélùn)•同步放化疗联合顺铂长春瑞宾及西妥昔单抗时可行的•长春瑞宾不能选择最大剂量•毒性在预期内•3月后治疗结果令人鼓舞力比泰卡铂同步3D适形放疗后以力比泰卡铂巩固化疗治疗中国局部(júbù)晚期NSCLC患者摘要e18502：研究(yánjiū)设计摘要(zhāiyào)e18502：研究结果–缓解情况摘要(zhāiyào)e18502：研究结果–不良反应放疗在早期(zǎoqī)NSCLC的进展同步放化疗与靶向药物治疗NSCLC的进展同步放化疗联合培美曲塞治疗NSCLC的研究进展同步放化疗在晚期NSCLC的进展15-year(very)long-termsurvival(VLTS)andcompetingrisks(CR)analysisofinduction(IND)chemotherapy(CTx)withthreecyclescisplatin(P)/etoposide(E)followedbyconcurrent(cc)chemoradiation(CTx/RTx)PE/45Gy(1.5Gybid)plussurgery(S)=TRIMODALITY–phase-IIWestGermanCancerCentre(WGCC)trial(JCO98).R.Hepp1T.C.Gauler2C.Poettgen1S.Korfee2S.Bildat2G.Stamatis3S.Seeber4H.Wilke4V.Budach5M.Stuschke1W.E.E.Eberhardt2试验(shìyàn)设计OS(stag